Clinical Trial Update: [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001) [Phase 1]

View source ↗

Summary

Phase 1 PET tracer validation trial for [11C]MK-6884 in Alzheimer's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [11C]MK-6884 (MK-6884)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2019-02-28